Comment on 2 Clinical-Stage Biotech Stocks That Could Soar Next Week

2 Clinical-Stage Biotech Stocks That Could Soar Next Week

Although it's never a good idea to try to time the market, there are undoubtedly better times than others when it comes to buying clinical-stage biotech stocks. If you buy too early, for instance, you can end up having to wait years before a company reaches an important clinical milestone, and that could mean enduring multiple rounds of dilution as well. With this theme in mind, I think investors may want to take a close look at the clinical-stage biotechs Galectin Therapeutics (NASDAQ: GALT) and Verastem (NASDAQ: VSTM) heading into next week.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News